Uncategorized

McAfee predicts emerging threats of 2011

McAfee Inc. on Tuesday unveiled its 2011 Threat Predictions report, outlining top threats its researchers foresee for the coming year from a list that includes location-based services, Android and iPhone. Santa Clara-based McAfee (NYSE:MFE) said Mountain View-based Google‘s (NASDAQ:GOOG) Android and Google TV are expected to become major targets for cybercriminals. Also on the list […]

Read more

Biotech companies promise 1,000 jobs

Thirty life sciences companies in Massachusetts have pledged to create nearly 1,000 jobs next year in exchange for $23.9 million in tax incentives awarded Thursday by a state board. The awards work out to a public subsidy of about $23,900 per job. The Massachusetts Life Sciences Center Board awarded the tax incentives under a program […]

Read more

Cambridge Heart takes in $2.9M

Cambridge Heart Inc. has raised $2.9 million in a private placement, the company reported in a press release today The Tewksbury-based developer of diagnostic heart tests for cardiac disease, said the deal consisted half of shares of common stock and half of warrants to purchase stock at a future date. “The proceeds from this transaction […]

Read more

Raytheon BBN working on Star Trek tech

If you thought inventing the Internet was a big enough accomplishment that you can rest on your laurels, you can’t work for Raytheon BBN Technologies — the actual inventors of said Internet. DARPA agrees, and is now funding Raytheon BBN in a program to create super high-capacity broadband encrypted communications that is all but unbreakable, […]

Read more

Sanofi-Aventis does deal with Avila

Avila Therapeutics, Inc., a privately held biotechnology company, will receive an upfront payment of up to $40 million from French drug maker Sanofi-aventis, as part of a research collaboration aimed at developing cancer drugs. Cambridge, Mass-based biotech will receive up to $154 million in milestone payments for any drug that is eventually approved. Waltham, Mass.-based […]

Read more

Semprus BioSciences raises Series B funds

Cambridge-based biomedical company focused on antibacterial coatings Semprus BioSciences Inc. has closed on an $18 million Series B financing roubnd, led by SR One, the corporate venture capital arm of GlaxoSmithKline, and Foundation Medical Partners. According to Semprus officials, 5AM Ventures and Pangaea Ventures, both of whom invested in the company’s Series A financing, participated […]

Read more

Compare